|
Baseline characteristic
|
MK-2206 dosing cohort
|
|---|
|
45 mg QOD
|
60 mg QOD
|
135 mg QW
|
200 mg QW
|
All cohorts
|
|---|
|
(n = 3)
|
(n = 11)
|
(n = 11)
|
(n = 6)
|
(N = 31)
|
|---|
|
Gender, n (%)
|
|
Male
|
0 (0.0)
|
1 (9.1)
|
0 (0.0)
|
2 (33.3)
|
3 (9.7)
|
|
Female
|
3 (100.0)
|
10 (90.9)
|
11 (100.0)
|
4 (66.7)
|
28 (90.3)
|
|
Age (years)
|
|
Median
|
44
|
55.5
|
49
|
48.5
|
51.5
|
|
Range
|
36 to 52
|
44 to 67
|
37 to 61
|
38 to 59
|
36 to 67
|
|
Cancer type, n (%)
|
|
Breast
|
3 (100.0)
|
10 (90.9)
|
11 (84.6)
|
3 (50.0)
|
27 (87.1)
|
|
Gastric
|
0 (0.0)
|
1 (9.1)
|
0 (0.0)
|
3 (50.0)
|
4 (12.9)
|
|
Cancer stage, n (%)
|
|
Intravenous
|
3 (100.0)
|
11 (100.0)
|
11 (100.0)
|
6 (100.0)
|
31 (100.0)
|
|
ECOG status, n (%)
|
|
0
|
3 (75.0)
|
7 (63.6)
|
10 (91.0)
|
4 (66.7)
|
24 (77.4)
|
|
1
|
0 (0.0)
|
4 (36.4)
|
1 (9.0)
|
2 (33.3)
|
7 (22.6)
|
|
Number of prior therapies, n (%)
|
|
1 or 2
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
2 (33.3)
|
2 (6.5)
|
|
≥3
|
3 (100.0)
|
11 (100.0)
|
11 (100.0)
|
4 (66.7)
|
29 (93.5)
|
- ECOG, Eastern Cooperative Oncology Group; QOD, every other day; QW, every week.
